Compare Agilent Technologies Inc (A) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs InMode Ltd — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while InMode Ltd trades at $15.16 (market cap $873.13M). The key difference: Agilent Technologies Inc is far larger — about 48.1× InMode Ltd's market cap, and Agilent Technologies Inc pays a 0.69% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| A | INMD | |
|---|---|---|
Market Cap | $42.00B | $873.13M |
Sector | Health | Technology |
52-Week High | $157.20 | $16.62 |
52-Week Low | $110.24 | $12.76 |
Enterprise Value | $43.55B | $376.47M |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.
The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
